1 / 14

Novartis in Italy

Novartis in Italy. Dimensions, role and resources. Commitment to innovation. Novartis 2012 data. Novartis is a global leader in the area of healthcare. Novartis is based in Basel and present in more than 140 countries. Profile of a protagonist Divisions.

jara
Download Presentation

Novartis in Italy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Novartis in Italy Dimensions, role and resources. Commitment to innovation

  2. Novartis2012 data Novartis is a global leader in the area of healthcare Novartis is based in Basel and present in more than 140 countries | Novartis in Italy | Dimensions, role and resources | Commitment to innovation | Business Use Only

  3. Profile of a protagonistDivisions The only large Group active in all healthcare sectors Pharmaceuticals Alcon Sandoz (generics) Vaccines & Diagnostics Consumer Healthy (OTC and Animal Health) (% of global turnover – 2012) | Novartis in Italy | Dimensions, role and resources | Commitment to innovation | Business Use Only

  4. Rovereto (Trento) Origgio (Varese) Rosia (Siena) Siena Rome Torre Annunziata (Naples) Site Site with Production Site with Production and Research Novartis in ItalyGroup numbers and presence One of the national market leaders in all business areas Milan | Novartis in Italy | Dimensions, role and resources | Commitment to innovation | Business Use Only

  5. Clinical research, a constantly increasing commitmentPharma, 2012: trials and dedicated resources • 35.8 million euros • 312 trials • more than 39,000 patients | Novartis in Italy | Dimensions, role and resources | Commitment to innovation | Business Use Only

  6. New molecules Towards the futureOne of the mostpromising R&D pipelines in the sector New indications New formulations 2016  2017 2015 2014 2013 AIN457Psoriasis AFQ056Fragile X syndrome BKM120Breast carcinoma BYM338sIBM15 ATI355Spinal cord lesions KAE609Malaria CTL019Leukemia LBH589Multiple myeloma LCQ908FCS4 MEK162Solid tumours AUY922Solid tumours LFF571Clostridium difficile infections LCZ696Hypertension LGX818Solid tumours LDE225Basal cell carcinoma PKC412AML7 BAF312Multiple sclerosis LCI699Cushing’s disease RLX030*Acute heart failure Everolimus DLBCL8 BCT197COPD14 LIK066Type-2 diabetes LDK378NSCLC5 ACZ885Secondary prevention of cardiovascular events BEZ235Solid tumours QAW039 Asthma TKI258Renal cell carcinoma EverolimusFirst-line treatment of HER2+ breast carcinoma EverolimusNon-functioning pulmonary and GI NETs9 FingolimodCIDP16 QGE031 Allergic diseases BGS649OHH18 EverolimusSecond-line treatment of HER2+ breast carcinoma AIN457Arthritides (RA, AS, PA)6 EverolimusTSC-associated epilepsy10 RanibizumabCNV and ME17 EverolimusHCC1 AFQ056PD-LID11 AIN457Multiple sclerosis RuxolitinibPolycythemia vera BYL719Solid tumours TKI258Solid tumours PKC412ASM12 Pasireotide LAR2Acromegaly LCZ696Heart failure CAD106Alzheimer’s disease BKM120Solid tumours OmalizumabCSU3 Aliskiren Heart failure13 DEB025HCV infection LDE225Solid tumours QMF149 COPD14 NilotinibTreatment-free CML 1 Hepatocellular carcinoma 2 Long-acting release 3 Chronic spontaneous urticaria 4 Familial chylomicronemia syndrome 5 Non-small-cell lung carcinoma 6 Rheumatois arthritis, ankylosing spondylitis, psoriatic arthritis 7 Acute myeloid leukemia Diffuse large B cell leukemia Non-functioning pulmonary and gastrointestinal neuroendocrine tumours * Presentato in UE a dicembre 2012 QMF149 Asthma Pasireotide LAR2 Cushing’s disease 15 Sporadic inclusion body myositis 16 Chronic inflammatory demelinating polyneuropathy 17 Choroidal neovascularisation (CNV) and macular edema (ME) not due to age-related macular degeneration, diabetic macular edema, retinal venous occlusion or pathological myopia 18 Obesity-associated hypogonadotropic hypogonadism 10 Tuberous sclerosis-associated epilepsy 11 Parkinson’s disease, levodopa-induced dyskinesia 12 Aggressive systemic mastocytosis 13 Reduction in deaths/hospitalisations due to cardiovascular causes in patients with chronic heart failure 14 Chronic obstructive pulmonary disease | Novartis in Italy | Dimensions, role and resources | Commitment to innovation | Business Use Only

  7. Basic researchThe role of Novartis Italy in vaccines • Siena, a world centre of excellencefor innovative vaccine research: • 512 researchers • In 2012, its position as leader in the fightagainstmeningitiswasconfirmed: • The first and onlybroad-spectrum vaccine againsttype-B meningitiswasapproved in Europe • Together with the conjugated vaccine againstserogroups A, C, W135 and Y, Novartis vaccines help protectagainst the fiveprincipalserogroups of meningococcus | Novartis in Italy | Dimensions, role and resources | Commitment to innovation | Business Use Only

  8. Production: a strategic resourceIndustrial sites in Italy • Torre AnnunziataA strategic international centre, one of the largest pharmaceutical production sites in Southern Italy. • Exports to more than 100 international markets • Drugs in solid form: 100 million packages in 2012 • RoveretoQuality and safety in the production of active ingredients. • One of the most important industrial sites in Trentino • Production of mycophenolic acid for the immunosuppressant Myfortic • 40% of the global production of tiamulin (a veterinary drug) • HSE investments: 40 million euros in 15 years (of a total of 200 million euros), seven of which in only the last two years • Siena and RosiaVaccines, an essential factor for the future of healthcare. • Novartis Vaccines makes Italy one of the few EU member states that produces vaccines • In 2012, 400 million vaccine doses were produced, 60% Novartis’ entire production in the sector | Novartis in Italy | Dimensions, role and resources | Commitment to innovation | Business Use Only

  9. Innovation for the right to healthcareNovartis Institute for Tropical Diseases • The NITD in Singapore is the only large private research centre working on the forgotten diseases of the Southern world • More than 100 researchers • Focus on Dengue fever, malaria and tuberculosis • Results and objectives • Significant progress made in various clinical trials of new compounds against the malaria caused by Plasmodium falciparum and P. vivax in 2012 • 2013: To complete the most advanced trials successfully and continue the development of candidate substances against malaria | Novartis in Italy | Dimensions, role and resources | Commitment to innovation | Business Use Only

  10. Innovation for the right to healthcare Novartis Vaccines Institute for Global Health • The NVGH in Siena is responsible for the R&D of vaccines against the diseases that mainly affects developing countries • Focus on enteric infectious diseases • Results 2012: • Process developed for a vaccine against non-typhoid salmonella. Demonstrated bactericidal activity against the two main serotypes in Africa • Pilot prodution process for the vaccine against Shigella | Novartis in Italy | Dimensions, role and resources | Commitment to innovation | Business Use Only

  11. The right to healthcareSocial responsibility • Social sustainability for Novartis • Access to drugs • Novartis promotes educational and healthcare projects in developing countries directly and through the Novartis Foundation for Sustainable Development • International programmes against malaria, tuberculosis and leprosy • 2012: Novartis’ drug access programmes: • 2 billion dollars • More than 100 million patients | Novartis in Italy | Dimensions, role and resources | Commitment to innovation | Business Use Only

  12. Innovation and social responsibilityThe fight against malaria • Malaria: Novartis in the front line • Coartem and Coartem Dispersibile supplied at cost price to international organisations, governments and the populations of the most affected countries (mainly in Africa) • The fixed-dose artemisinin-based combination is acknowledged to be the most efficacious antimalarial agent in places in which the drug-resistant forms of the disease are most widespread The demand for Coartem is constantly growing • In 2002: 1 million treatments • In 2012: 95 million treatments Since 2001: 600 million treatments It is estimated that one million lives have been saved, above all children and newborns | Novartis in Italy | Dimensions, role and resources | Commitment to innovation | Business Use Only

  13. Dynamo CampA partnership based on patient centrality • Novartis supports Dynamo Camp, a Tuscan organisation that provides free holidays for Italian and foreign children aged 7-17 years affected by severe and chronic oncohematological and neurological diseases. • Since 2007, numerous projects have been implemented: • Novartis Community Partnership Day: an annual day of voluntary work in favour of Dynamo Camp (fund raising in Milan; manual work at the oasis in Tuscany) • Christmas donations • 2011: Camping Lab, a new structure immersed in nature • 2012: A continuing medical education programme on recreational therapy aimed at healthcare professionals and future Dynamo volunteers | Novartis in Italy | Dimensions, role and resources | Commitment to innovation | Business Use Only

  14. Partner for development The role of Novartis in Italy • Research and Development • In Italy, world centre for vaccine R&D • Novartis primary in pharmaceutical clinical development • Production • Three large international-level production units • Exports in constant expansion • Healthcare • Drugs, ophthalmic products, generics, vaccines, OTC: a complete offer • Many new drug launches every year • Society • NVGH, no-profit vaccine research centre • Educational/sensitisation campaigns | Novartis in Italy | Dimensions, role and resources | Commitment to innovation | Business Use Only

More Related